OncoTRACE

OncoTRACE   OncoTRACE

 

OncoTRACE este metoda noastra ultrasensibila si individualizata de monitorizare a cancerului dumneavoastra, utilizand biomarcherii prezenti in biopsii lichide (un simplu test sangvin). Aceasta metoda furnizeaza indicii timpurii pentru alegerea unui tratament adecvat.

Descriere

OncoTRACE (RUO) furnizeaza o analiza diferentiata a genomului tumoral si a genomului din ADN-ul normal al pacientului. Analiza consista in efectuarea urmatoarelor trei etape:
* Identificarea biomarcherilor specifici tumorii unui pacient: biomarcherii personalizati pot fi mutatii, rearanjari genetice, etc..
* Validarea biomarcherilor descoperiti si dezvoltarea unui test pentru detectia lor in sange
* Analiza semi-cantitativa in rutina a biomarcherilor personalizati, dintr-o simpla proba de sange.

Acest test este furnizat doar in scop de cercetare, desi utilitatea biomarcherilor din biopsiile lichide a fost validata in diferite articole stiintifice. Descoperirea si validarea biomarcherilor personalizati este o etapa pentru care timpul necesar este greu de estimat de la bun inceput, care variaza de la un pacient la altul. Odata ce testul a fost validat, analiza biomarcherilor dintr-o proba de sange este foarte rapida (mai putin de 5 zile).

Avantaje

Avantajele diagnosticului acestei noi abordari sunt evidente:
* Specificitate extrema: sunt marcheri personalizati, specifici tumorii pacientului
* Foarte rapid (analiza in mai putin de 5 zile, dupa ce biomarcherii personalizati au fost validati)
* Fara interventii invazive masive: e nevoie doar de o simpla proba de sange
* Sensibilitate marita, permitand o detectie timpurie a recidivei (tehnicile de imagerie permit detectia unei tumori doar daca e mai mare de 0,5 cm). De aceea OncoTRACE poate detecta o recidiva a tumorii cu pana la 6 luni inainte de a putea fi detectata prin tehnici de imagerie.
* Informatia este semi-cantitativa, ceea ce inseamna ca diagnoza este mai precisa si putem avea indicii timpurii ale raspunsului la tratamentul ales.

 

 

OncoTRACE is a test based on circulating tumor DNA (ctDNA) in liquid biopsies (principally blood). It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears. This assay is customized for each patient, as it contains personal cancer-specific markers and variants identified in a previous genomic analysis.

 

00:00Current time01:11

Description

In 2013 OncoDNA became the first company to personalize a specific OncoTRACE test for every patient (a recent publication in 2017 in Nature demonstrates the efficacy of such an approach).

Read the publication

The test is customized for each patient, by first selecting a set of patient-specific variants, identified in the tumor by a previous genetic test (like our OncoSTRAT&GO solution or tests like FoundationOne® from Foundation Medicine, CGP+ from Caris Molecular Intelligence or Guardant360 from Guardant Health). The first set of markers is associated with a second panel of specific variants, often related to resistance or sensitivity to targeted therapies, then with a third set of markers found frequently in the early development of the tumor. 3 levels of personalization, one powerful monitoring tool.

Download the product sheet

Download the genes panel

 

Advantages

A personalized, unique panel is manufactured for each patient.  The panel can then be used repeatedly on any liquid biopsy sample (usually blood).  For the first time this minimally invasive technique enables, the oncologist to follow the treatment response very closely, detect relapse earlier than routine imaging technologies and identify new targets if the cancer grows resistant to the current therapy.

 

Logistics

Just send us a  blood sample (2 Streck tubes each containing 10 ml).

Download sample prep protocol


Pret

Pretul unui pachet de analize OncoTRACE este de 8250 lei, fara TVA.


Nu am gasit nici un produs care se potriveste selectiei.
© S.C. Bio Zyme S.R.L. Toate Drepturile Rezervate.